Strattera Related Published Studies
Well-designed clinical trials related to Strattera (Atomoxetine)
Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. [2009.11]
Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. [2009.10]
Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. [2009.09]
Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia. [2009.07.01]
Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder. [2009.06]
Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. [2009.05]
Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. [2009.04.01]
A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. [2009.04]
Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naive Swedish children and adolescents. [2009.04]
Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo. [2009.03]
Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. [2009.02]
Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. [2009]
Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. [2008.11]
Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacy. [2008.09.15]
Abuse liability assessment of atomoxetine in a drug-abusing population. [2008.05.01]
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. [2008.02]
A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. [2008.02]
Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. [2007.11.01]
High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses. [2007.09]
Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. [2007.09]
A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder. [2007.08]
Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. [2007.08]
Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure. [2007.07]
Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD. [2007.07]
Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. [2007.04]
Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD. [2007.03.01]
Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. [2007.03]
A pilot study of the effects of atomoxetine on driving performance in adults with ADHD. [2007.02]
Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. [2007.01]
Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. [2006.12]
Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder. [2006.12]
Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning. [2006.11]
Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. [2006.10]
Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. [2006.04]
Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. [2006.03]
Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder. [2006.03]
A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. [2006.02]
Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD. [2005.10]
Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. [2005.09]
Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder. [2005.08]
Emotional dysregulation in adult ADHD and response to atomoxetine. [2005.07.15]
A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. [2005.07]
[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents] [2005.05]
Investigator ratings of ADHD symptoms during a randomized, placebo-controlled trial of atomoxetine: a comparison of parents and teachers as informants. [2005.05]
Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. [2005.03]
Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. [2005.03]
Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. [2004.10]
Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. [2004.07]
Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. [2004.07]
Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. [2004.02]
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. [2003.01.15]
Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. [2002.12]
Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. [2002.12]
Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. [2002.11]
Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. [2002.07]
Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. [2001.11]
Well-designed clinical trials possibly related to Strattera (Atomoxetine)
The reliability and validity of self- and investigator ratings of ADHD in adults. [2008.05]
Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL). [2007.11]
A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. [2007.03.01]
Emotional expression during attention-deficit/hyperactivity disorders treatment: initial assessment of treatment effects. [2007.02]
Remission versus response as the goal of therapy in ADHD: a new standard for the field? [2006.11]
Attention-deficit/hyperactivity disorder: use of cognitive evoked potential (P300) to predict treatment response. [2006.09]
Dopamine transporter genotype influences the physiological response to medication in ADHD. [2006.08]
Pharmacotherapy of adult ADHD. [2005.05]
The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. [2004.06]
Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. [1998.05]
Other research related to Strattera (Atomoxetine)
Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study. [2009.11]
Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physicians. [2009.08.24]
A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder. [2009.08]
Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. [2009.02.04]
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. [2009.01.30]
Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder : A randomized, double-blind, placebo-controlled study in stimulant-naive Swedish children and adolescents. [2009.01.20]
Simulated driving changes in young adults with ADHD receiving mixed amphetamine salts extended release and atomoxetine. [2009.01]
Simulated Driving Changes in Young Adults With ADHD Receiving Mixed Amphetamine Salts Extended Release and Atomoxetine. [2008.09.24]
Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. [2008.09]
Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. [2008.07.01]
Atomoxetine increases histamine release and improves learning deficits in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat. [2008.06]
Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. [2008.06]
Both atomoxetine and stimulants improve quality of life in an ADHD population treated in a community clinic. [2008.06]
A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. [2008.05]
Atomoxetine for treatment of marijuana dependence: a report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study. [2008.04.01]
Development of tics in a thirteen-year-old male following atomoxetine use. [2008.04]
Post-injury atomoxetine treatment improves cognition following experimental traumatic brain injury. [2008.03]
Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study. [2008.02]
Latino versus Caucasian response to atomoxetine in attention-deficit/hyperactivity disorder. [2008.02]
Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. [2008.02]
Atomoxetine treatment of ADHD in children with comorbid tourette syndrome. [2008.01]
Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence. [2008]
Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. [2008]
Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study. [2007.12]
Atomoxetine Treatment of ADHD in Children With Comorbid Tourette Syndrome. [2007.10.12]
Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele. [2007.10]
Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. [2007.10]
Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. [2007.10]
A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder. [2007.09.27]
[Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children] [2007.09]
Forecasting Three-Month Outcomes in a Laboratory School Comparison of Mixed Amphetamine Salts Extended Release (Adderall XR) and Atomoxetine (Strattera) in School-Aged Children With ADHD. [2007.08]
Atomoxetine treatment of ADHD in Tourette syndrome: reduction in motor cortex inhibition correlates with clinical improvement. [2007.08]
Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele. [2007.07.04]
Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. [2007.07]
Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. [2007.06.16]
|
